Unity Biotechnology Inc. (NASDAQ:UBX) went down by -5.00% from its latest closing price compared to the recent 1-year high of $3.64. The company’s stock price has collected -10.44% of loss in the last five trading sessions.
Is It Worth Investing in Unity Biotechnology Inc. (NASDAQ :UBX) Right Now?
Plus, the 36-month beta value for UBX is at 0.71. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Unity Biotechnology Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.83, which is $7.4 above the current price. UBX currently public float of 137.51M and currently shorts hold a 1.28% ratio of that float. Today, the average trading volume of UBX was 3.82M shares.
UBX’s Market Performance
UBX stocks went down by -10.44% for the week, with a monthly drop of -30.26% and a quarterly performance of -27.92%, while its annual performance rate touched -85.58%. The volatility ratio for the week stands at 5.38% while the volatility levels for the past 30 days are set at 7.47% for Unity Biotechnology Inc. The simple moving average for the period of the last 20 days is -13.45% for UBX stocks with a simple moving average of -55.33% for the last 200 days.
Analysts’ Opinion of UBX
Mizuho, on the other hand, stated in their research note that they expect to see UBX reach a price target of $7, previously predicting the price at $5. The rating they have provided for UBX stocks is “Buy” according to the report published on November 10th, 2021.
Citigroup gave a rating of “Buy” to UBX, setting the target price at $6 in the report published on June 28th of the previous year.
UBX Trading at -36.41% from the 50-Day Moving Average
After a stumble in the market that brought UBX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.31% of loss for the given period.
Volatility was left at 7.47%, however, over the last 30 days, the volatility rate increased by 5.38%, as shares sank -25.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.72% lower at present.
During the last 5 trading sessions, UBX fell by -10.44%, which changed the moving average for the period of 200-days by -75.55% in comparison to the 20-day moving average, which settled at $0.4844. In addition, Unity Biotechnology Inc. saw -70.86% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at UBX starting from Ghosh Anirvan, who sale 13,706 shares at the price of $0.48 back on Sep 14. After this action, Ghosh Anirvan now owns 983,210 shares of Unity Biotechnology Inc., valued at $6,579 using the latest closing price.
Dananberg Jamie, the Chief Medical Officer of Unity Biotechnology Inc., sale 10,923 shares at $0.48 during a trade that took place back on Sep 14, which means that Dananberg Jamie is holding 661,213 shares at $5,243 based on the most recent closing price.
Stock Fundamentals for UBX
Current profitability levels for the company are sitting at:
- -1184.47 for the present operating margin
- +39.80 for the gross margin
The net margin for Unity Biotechnology Inc. stands at -1269.34. Equity return is now at value -113.90, with -51.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.45.